Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 11 (4), 282-6

New Antimicrobial Agents for Methicillin-Resistant Staphylococcus Aureus

Affiliations
  • PMID: 20001879
Review

New Antimicrobial Agents for Methicillin-Resistant Staphylococcus Aureus

Marin H Kollef. Crit Care Resusc.

Abstract

In bacterial and fungal infections, optimal outcomes are obtained through the timely provision of adequate antimicrobial coverage in an initial anti-infective treatment regimen. However, selecting appropriate antimicrobial regimens to treat infections in the intensive care unit is challenging because of the expansion of antibiotic resistance. Multidrug anti-infective regimens are typically needed to adequately cover common important pathogens in ICUs. Here, we describe novel antibacterial agents in the late stages of clinical development that show potential for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These include the fifth-generation cephalosporins, ceftaroline and ceftobiprole; the glycopeptides, dalbavancin, oritavancin, and telavancin; and iclaprim.

Comment in

  • Gram Versus Gram
    E Stachowski. Crit Care Resusc 12 (1), 69; author reply 69. PMID 20196719.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback